Value proposition

OKYO focuses on novel GPCR based therapeutics for eye diseases of unmet need and non-opioid analgesics for chronic pain.

OKYO Pharma focuses on:
A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis.
An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and chronic pain management using novel topical and nasal formulations.